Results Median GFR was 66.5 (interquartile range, 40.0–88.3) ml/min per 1.73 m 2. Median
sclerostin level was 53.5 (interquartile range, 37.5–77.2) pmol/L, was higher in patients with …

Background: The chronic kidney disease (CKD)-mineral and bone disorder (MBD)
syndrome is an important contributor to the CKD-associated cardiovascular disease and …

Background: Sclerostin is a potent inhibitor of bone formation, but the meaning of its serum
levels remains undetermined. We evaluated the association between sclerostin levels and …

Context: Sclerostin serum levels are increased in patients with chronic kidney disease
(CKD). Osteoporosis and CKD often occur simultaneously. Currently antisclerostin …

Abstract Background Sclerostin is a Wnt pathway antagonist regulating osteoblast activity
and bone turnover, and it plays a role in cardiovascular calcification processes. Previous …

Background and aims Sclerostin is a circulating inhibitor of the Wnt/β-catenin pathway and
may have a role in chronic kidney disease (CKD)-mineral and bone disorder. Blood …

Background: Sclerostin is an osteocyte hormone that decreases osteoblastogenesis.
Sclerostin may play a key role in osteoporosis and also in vascular calcification (VC). In …

Background and aim Chronic kidney disease mineral and bone disorder (CKD-MBD) is
associated with increased morbidity and mortality. Several cross-sectional studies …

Aim The purpose of this study was to investigate the possible association of circulating
concentrations of sclerostin with abdominal aortic calcification (AAC) and cardiovascular …

Context: Vascular calcification (VC) is prevalent and progressive in renal transplant
recipients (RTRs). Recent cross-sectional data suggest that activated Wnt signaling …